Evidence map›Paper›PMID 26062653›Full record

ArticleOncotarget2015

Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.

Lyndsay V Rhodes, Elizabeth C Martin, H Chris Segar, David F B Miller, Aaron Buechlein, Douglas B Rusch, Kenneth P Nephew, Matthew E Burow, Bridgette M Collins-Burow

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 118 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Lyndsay V RhodesDepartment of Biological Sciences, Florida Gulf Coast University, Fort Myers, FL, USA.
Elizabeth C MartinDepartment of Medicine, Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA.
H Chris SegarDepartment of Medicine, Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA.
David F B MillerMedical Sciences and Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Bloomington, IN, USA.
Aaron BuechleinIndiana University Center for Genomics and Bioinformatics, Bloomington, IN, USA.
Douglas B RuschIndiana University Center for Genomics and Bioinformatics, Bloomington, IN, USA.
Kenneth P NephewMedical Sciences and Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Bloomington, IN, USA.
Matthew E BurowDepartment of Medicine, Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA.
Bridgette M Collins-BurowDepartment of Medicine, Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA.
Tulane University · USIndiana University Bloomington · USFlorida Gulf Coast University · USIndiana University School of Medicine

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBPP20RR020152 · NCRR · TULANE UNIVERSITY OF LOUISIANA · PI DEININGER, PRESCOTT L. · 2004 to 2011
$17.0M
Predicting Drug Resistance in Cancer Genomes by DMA Methylation ProfilingU54CA113001 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HUANG, TIM H.-M. · 2004 to 2014
$16.1M
Mentoring a Cancer Genetics ProgramP20GM103518 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI DEININGER, PRESCOTT L. · 2012 to 2013
$4.3M
MEK5-Erk5 in breast cancer resistanceR01CA125806 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI BUROW, MATTHEW E. · 2010 to 2014
$1.5M
NCI NIH HHS CA113001-07NCI NIH HHS CA125806NCI NIH HHS R01 CA125806NCI NIH HHS U54 CA113001NCRR NIH HHS P20 RR020152NCRR NIH HHS P20RR020152NIGMS NIH HHS 1 U54 GM104940NIGMS NIH HHS P20 GM103518NIGMS NIH HHS P20GM103518NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

Epithelial to mesenchymal transition (EMT) involves loss of an epithelial phenotype and activation of a mesenchymal one. Enhanced expression of genes associated with a mesenchymal transition includes ZEB1/2, TWIST, and FOXC1. miRNAs are known regulators of gene expression and altered miRNA expression is known to enhance EMT in breast cancer. Here we demonstrate that the tumor suppressive miRNA family, miR-200, is not expressed in triple negative breast cancer (TNBC) cell lines and that miR-200b-3p over-expression represses EMT, which is evident through decreased migration and increased CDH1 expression. Despite the loss of migratory capacity following re-expression of miR-200b-3p, no subsequent loss of the conventional miR-200 family targets and EMT markers ZEB1/2 was observed. Next generation RNA-sequencing analysis showed that enhanced expression of pri-miR-200b lead to ectopic expression of both miR-200b-3p and miR-200b-5p with multiple isomiRs expressed for each of these miRNAs. Furthermore, miR-200b-5p was expressed in the receptor positive, epithelial breast cancer cell lines but not in the TNBC (mesenchymal) cell lines. In addition, a compensatory mechanism for miR-200b-3p/200b-5p targeting, where both miRNAs target the RHOGDI pathway leading to non-canonical repression of EMT, was demonstrated. Collectively, these data are the first to demonstrate dual targeting by miR-200b-3p and miR-200b-5p and a previously undescribed role for microRNA processing and strand expression in EMT and TNBC, the most aggressive breast cancer subtype.

Indexed as

Antigens, CDBase SequenceCadherinsCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionFemaleForkhead Transcription FactorsGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansMCF-7 CellsMicroRNAsNuclear ProteinsRepressor Proteinsrho Guanine Nucleotide Dissociation Inhibitor alphaAntigens, CDARHGDIA protein, humanCadherinsCDH1 protein, humanForkhead Transcription FactorsFOXC1 protein, humanHomeodomain ProteinsMicroRNAsMIRN200 microRNA, humanNuclear ProteinsRepressor Proteinsrho Guanine Nucleotide Dissociation Inhibitor alphaTranscription FactorsTWIST1 protein, humanTwist-Related Protein 1ZEB1 protein, humanZEB2 protein, humanZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2isomiRsmiRNA biogenesisRHOGDIstar strandtriple negative breast cancer

Identifiers

PMID26062653
PMCPMC4599295
OpenAlexW1925281100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.